These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 33899152

  • 1. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Peñas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M.
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):971-982. PubMed ID: 33899152
    [Abstract] [Full Text] [Related]

  • 2. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Thyssen JP, Buhl T, Fernández-Peñas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Ständer S.
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1599-1611. PubMed ID: 34275122
    [Abstract] [Full Text] [Related]

  • 3. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI.
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [Abstract] [Full Text] [Related]

  • 4. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H, Bukhalo M, Smith S.
    J Cutan Med Surg; 2022 May; 26(3):262-266. PubMed ID: 35086348
    [Abstract] [Full Text] [Related]

  • 5. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF.
    Health Qual Life Outcomes; 2021 Oct 23; 19(1):247. PubMed ID: 34688290
    [Abstract] [Full Text] [Related]

  • 6. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
    Thyssen JP, Werfel T, Barbarot S, Hunter HJA, Pierce E, Sun L, Cirri L, Buchanan AS, Lu N, Wollenberg A.
    J Dermatolog Treat; 2023 Dec 23; 34(1):2190430. PubMed ID: 36912484
    [Abstract] [Full Text] [Related]

  • 7. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K.
    JAMA Dermatol; 2021 Jun 01; 157(6):691-699. PubMed ID: 33978711
    [Abstract] [Full Text] [Related]

  • 8. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
    Masuda K, Delozier AM, Kolodsick J, Buchanan A, Pink AE, Sun L, Wang Z, Stingeni L, Thac I D.
    Eur J Dermatol; 2022 Apr 01; 32(2):237-243. PubMed ID: 35866910
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
    Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S, Pierce E, Chen YF, Chen S, Eichenfield L.
    J Eur Acad Dermatol Venereol; 2023 May 01; 37(5):1036-1045. PubMed ID: 36514996
    [Abstract] [Full Text] [Related]

  • 10. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, Silverberg JI, Rueda MJ, DeLozier AM, Pierce E, Yang FE, Sun L, Ball S, Tauber M, Paul C.
    J Eur Acad Dermatol Venereol; 2021 Jul 01; 35(7):1543-1552. PubMed ID: 33834521
    [Abstract] [Full Text] [Related]

  • 11. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
    Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, Schloebe A, Riedl E, Cork MJ.
    Clin Exp Dermatol; 2023 Jul 21; 48(8):881-888. PubMed ID: 37032446
    [Abstract] [Full Text] [Related]

  • 12. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
    Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, Spina L, Lu N, Grond S, Eyerich K.
    J Eur Acad Dermatol Venereol; 2024 Apr 21; 38(4):695-702. PubMed ID: 38041556
    [Abstract] [Full Text] [Related]

  • 13. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
    Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, Ding Y, Feely M, Nunes FP, Simpson EL.
    Dermatol Ther (Heidelb); 2022 Jan 21; 12(1):137-148. PubMed ID: 34846636
    [Abstract] [Full Text] [Related]

  • 14. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
    Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP.
    J Dermatolog Treat; 2023 Dec 21; 34(1):2161812. PubMed ID: 36546346
    [Abstract] [Full Text] [Related]

  • 15. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K.
    Br J Dermatol; 2020 Aug 21; 183(2):242-255. PubMed ID: 31995838
    [Abstract] [Full Text] [Related]

  • 16. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
    Wollenberg A, Lio P, Kleyn E, Bissonnette R, Jose Rueda M, Casillas M, Chen YF, Lu N, Schloebe A, Simpson E.
    Eur J Dermatol; 2022 Jul 01; 32(4):522-529. PubMed ID: 36301752
    [Abstract] [Full Text] [Related]

  • 17. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP, Bieber T, Kleyn CE, Nosbaum A, Grond S, Petto H, Riedl E, Wollenberg A.
    J Dermatolog Treat; 2023 Dec 01; 34(1):2216322. PubMed ID: 37345379
    [Abstract] [Full Text] [Related]

  • 18. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL.
    Am J Clin Dermatol; 2021 May 01; 22(3):395-405. PubMed ID: 33826132
    [Abstract] [Full Text] [Related]

  • 19. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.
    Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A.
    Healthcare (Basel); 2021 Nov 18; 9(11):. PubMed ID: 34828623
    [Abstract] [Full Text] [Related]

  • 20. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
    Lio PA, Simpson EL, Han G, Soung J, Ball S, Sun L, Casillas M, DeLozier AM, Ding Y, Eichenfield LF.
    J Dermatolog Treat; 2022 Jun 18; 33(4):2057-2062. PubMed ID: 34176407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.